Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.
Identifieur interne : 004294 ( Main/Exploration ); précédent : 004293; suivant : 004295Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.
Auteurs : RBID : pubmed:8786866English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Ependymoma (diagnosis), Ependymoma (metabolism), Ependymoma (radionuclide imaging), False Negative Reactions, Female, Humans, Magnetic Resonance Imaging, Male, Meningeal Neoplasms (diagnosis), Meningeal Neoplasms (metabolism), Meningeal Neoplasms (radionuclide imaging), Meningioma (diagnosis), Meningioma (metabolism), Meningioma (radionuclide imaging), Middle Aged, Neurilemmoma (diagnosis), Neurilemmoma (metabolism), Neurilemmoma (radionuclide imaging), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Receptors, Somatostatin (metabolism).
- MESH :
- chemical , analogs & derivatives : Octreotide.
- diagnosis : Ependymoma, Meningeal Neoplasms, Meningioma, Neurilemmoma.
- chemical , diagnostic use : Octreotide.
- metabolism : Ependymoma, Meningeal Neoplasms, Meningioma, Neurilemmoma, Receptors, Somatostatin.
- radionuclide imaging : Ependymoma, Meningeal Neoplasms, Meningioma, Neurilemmoma.
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, False Negative Reactions, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged.
Abstract
The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to surgery, 47 patients were investigated up to 24 h following the injection of 200 MBq 111In-octreotide. Tracer uptake was compared with the histological presence of meningioma. Histology revealed 43 meningiomas, 3 neurinomas and 1 ependymoma. A true-positive SRS result was obtained in 36 patients, in 13 of whom a tumour volume of < 10 ml was noted. A false-negative SRS result was obtained in seven patients, all of whom had a tumour volume of < 10 ml. Whereas MRI alone was decisive in 38 of 47 patients, it could only provide a differential diagnosis in the remaining 9 patients. A positive SRS result confirmed meningioma in five of these patients, and a negative SRS result excluded meningioma in the other four. Therefore, cases of SRS-negative meningioma do exist. Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results.
PubMed: 8786866
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.</title><author><name sortKey="Bohuslavizki, K H" uniqKey="Bohuslavizki K">K H Bohuslavizki</name><affiliation wicri:level="3"><nlm:affiliation>Clinic of Nuclear Medicine, Christian-Albrechts University, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Clinic of Nuclear Medicine, Christian-Albrechts University, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Brenner, W" uniqKey="Brenner W">W Brenner</name></author><author><name sortKey="Braunsdorf, W E" uniqKey="Braunsdorf W">W E Braunsdorf</name></author><author><name sortKey="Behnke, A" uniqKey="Behnke A">A Behnke</name></author><author><name sortKey="Tinnemeyer, S" uniqKey="Tinnemeyer S">S Tinnemeyer</name></author><author><name sortKey="Hugo, H H" uniqKey="Hugo H">H H Hugo</name></author><author><name sortKey="Jahn, N" uniqKey="Jahn N">N Jahn</name></author><author><name sortKey="Wolf, H" uniqKey="Wolf H">H Wolf</name></author><author><name sortKey="Sippel, C" uniqKey="Sippel C">C Sippel</name></author><author><name sortKey="Clausen, M" uniqKey="Clausen M">M Clausen</name></author><author><name sortKey="Mehdorn, H M" uniqKey="Mehdorn H">H M Mehdorn</name></author><author><name sortKey="Henze, E" uniqKey="Henze E">E Henze</name></author></titleStmt><publicationStmt><date when="1996">1996</date><idno type="RBID">pubmed:8786866</idno><idno type="pmid">8786866</idno><idno type="wicri:Area/Main/Corpus">004695</idno><idno type="wicri:Area/Main/Curation">004695</idno><idno type="wicri:Area/Main/Exploration">004294</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Diagnosis, Differential</term><term>Ependymoma (diagnosis)</term><term>Ependymoma (metabolism)</term><term>Ependymoma (radionuclide imaging)</term><term>False Negative Reactions</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Meningeal Neoplasms (diagnosis)</term><term>Meningeal Neoplasms (metabolism)</term><term>Meningeal Neoplasms (radionuclide imaging)</term><term>Meningioma (diagnosis)</term><term>Meningioma (metabolism)</term><term>Meningioma (radionuclide imaging)</term><term>Middle Aged</term><term>Neurilemmoma (diagnosis)</term><term>Neurilemmoma (metabolism)</term><term>Neurilemmoma (radionuclide imaging)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Receptors, Somatostatin (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Ependymoma</term><term>Meningeal Neoplasms</term><term>Meningioma</term><term>Neurilemmoma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Ependymoma</term><term>Meningeal Neoplasms</term><term>Meningioma</term><term>Neurilemmoma</term><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Ependymoma</term><term>Meningeal Neoplasms</term><term>Meningioma</term><term>Neurilemmoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Diagnosis, Differential</term><term>False Negative Reactions</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to surgery, 47 patients were investigated up to 24 h following the injection of 200 MBq 111In-octreotide. Tracer uptake was compared with the histological presence of meningioma. Histology revealed 43 meningiomas, 3 neurinomas and 1 ependymoma. A true-positive SRS result was obtained in 36 patients, in 13 of whom a tumour volume of < 10 ml was noted. A false-negative SRS result was obtained in seven patients, all of whom had a tumour volume of < 10 ml. Whereas MRI alone was decisive in 38 of 47 patients, it could only provide a differential diagnosis in the remaining 9 patients. A positive SRS result confirmed meningioma in five of these patients, and a negative SRS result excluded meningioma in the other four. Therefore, cases of SRS-negative meningioma do exist. Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8786866</PMID><DateCreated><Year>1996</Year><Month>09</Month><Day>20</Day></DateCreated><DateCompleted><Year>1996</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0143-3636</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>1996</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nuclear medicine communications</Title><ISOAbbreviation>Nucl Med Commun</ISOAbbreviation></Journal><ArticleTitle>Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.</ArticleTitle><Pagination><MedlinePgn>302-10</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to surgery, 47 patients were investigated up to 24 h following the injection of 200 MBq 111In-octreotide. Tracer uptake was compared with the histological presence of meningioma. Histology revealed 43 meningiomas, 3 neurinomas and 1 ependymoma. A true-positive SRS result was obtained in 36 patients, in 13 of whom a tumour volume of < 10 ml was noted. A false-negative SRS result was obtained in seven patients, all of whom had a tumour volume of < 10 ml. Whereas MRI alone was decisive in 38 of 47 patients, it could only provide a differential diagnosis in the remaining 9 patients. A positive SRS result confirmed meningioma in five of these patients, and a negative SRS result excluded meningioma in the other four. Therefore, cases of SRS-negative meningioma do exist. Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bohuslavizki</LastName><ForeName>K H</ForeName><Initials>KH</Initials><Affiliation>Clinic of Nuclear Medicine, Christian-Albrechts University, Kiel, Germany.</Affiliation></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Braunsdorf</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Behnke</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tinnemeyer</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hugo</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sippel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Clausen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mehdorn</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Henze</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>ENGLAND</Country><MedlineTA>Nucl Med Commun</MedlineTA><NlmUniqueID>8201017</NlmUniqueID><ISSNLinking>0143-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ependymoma</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">False Negative Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Meningeal Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Meningioma</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neurilemmoma</DescriptorName><QualifierName MajorTopicYN="N">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8786866</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004294 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004294 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8786866
|texte= Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8786866" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |